Literature DB >> 32268248

Pharmacy-based methadone dispensing and drive time to methadone treatment in five states within the United States: A cross-sectional study.

Paul J Joudrey1, Nicholas Chadi2, Payel Roy3, Kenneth L Morford4, Paxton Bach5, Simeon Kimmel6, Emily A Wang4, Susan L Calcaterra7.   

Abstract

BACKGROUND: Within the United States, there is a shortage of opioid treatment programs (OTPs), facilities which dispense methadone for opioid use disorder. It is unknown how pharmacy-based methadone dispensing, as available internationally, could affect methadone access. We aimed to compare drive times to the nearest OTP with drive times to the nearest chain pharmacy in urban and rural census tracts.
METHODS: Cross-sectional geospatial analysis of 2018 OTP location data and 2017 pharmacy location data. We included census tracts with non-zero population in Indiana, Kentucky, Ohio, Virginia, and West Virginia, states with highest rates of opioid overdose deaths. Our outcome was minimum drive time in minutes from census tract mean center of population to the nearest dispensing facility.
RESULTS: Among 7918 census tracts, median (IQR) drive time to OTPs increased from urban to increasingly rural census tract classification [16.1 min (10.2-25.9) to 48.4 min (34.0-63.3);p < .001]. Median (IQR) drive time to OTPs was greater than drive time to chain pharmacies among all census tracts: 19.6 min (11.6-35.1) versus 4.4 min (2.9-7.7) respectively; p < .001. The median (IQR) difference in drive time was greater for increasingly rural census tracts [11.5 min (6.1-19.2) to 35.2 min (19.6-49.7); p <.001] with pharmacy-based methadone dispensing.
CONCLUSION: Rural census tracts have disproportionately long drive times to OTPs. Drawing from policies to increase methadone access in countries like Canada and Australia, this geographic methadone disparity could be mitigated through implementation of pharmacy-based methadone dispensing.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Access; Methadone; Opioid use disorder; Pharmacy

Year:  2020        PMID: 32268248      PMCID: PMC7529685          DOI: 10.1016/j.drugalcdep.2020.107968

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  40 in total

1.  Automobile commuting duration and the quantity of time spent with spouse, children, and friends.

Authors:  Thomas J Christian
Journal:  Prev Med       Date:  2012-06-25       Impact factor: 4.018

2.  Access to treatment for opioid dependence in rural America: challenges and future directions.

Authors:  Stacey C Sigmon
Journal:  JAMA Psychiatry       Date:  2014-04       Impact factor: 21.596

Review 3.  Community pharmacies as sites of adult vaccination: A systematic review.

Authors:  Randall C Burson; Alison M Buttenheim; Allison Armstrong; Kristen A Feemster
Journal:  Hum Vaccin Immunother       Date:  2016-08-15       Impact factor: 3.452

4.  Barriers and facilitators to dispensing of intranasal naloxone by pharmacists.

Authors:  Ludmila N Bakhireva; Adriana Bautista; Sandra Cano; Shikhar Shrestha; Amy M Bachyrycz; Theresa H Cruz
Journal:  Subst Abus       Date:  2017-12-05       Impact factor: 3.716

5.  Trends and Patterns of Geographic Variation in Mortality From Substance Use Disorders and Intentional Injuries Among US Counties, 1980-2014.

Authors:  Laura Dwyer-Lindgren; Amelia Bertozzi-Villa; Rebecca W Stubbs; Chloe Morozoff; Shreya Shirude; Jürgen Unützer; Mohsen Naghavi; Ali H Mokdad; Christopher J L Murray
Journal:  JAMA       Date:  2018-03-13       Impact factor: 56.272

6.  Growth In Buprenorphine Waivers For Physicians Increased Potential Access To Opioid Agonist Treatment, 2002-11.

Authors:  Andrew W Dick; Rosalie L Pacula; Adam J Gordon; Mark Sorbero; Rachel M Burns; Douglas Leslie; Bradley D Stein
Journal:  Health Aff (Millwood)       Date:  2015-06       Impact factor: 6.301

7.  The impact of buprenorphine on treatment of opioid dependence in a Medicaid population: recent service utilization trends in the use of buprenorphine and methadone.

Authors:  Bradley D Stein; Adam J Gordon; Mark Sorbero; Andrew W Dick; James Schuster; Carrie Farmer
Journal:  Drug Alcohol Depend       Date:  2011-11-16       Impact factor: 4.492

Review 8.  Methadone Matters: What the United States Can Learn from the Global Effort to Treat Opioid Addiction.

Authors:  S L Calcaterra; P Bach; A Chadi; N Chadi; S D Kimmel; K L Morford; P Roy; J H Samet
Journal:  J Gen Intern Med       Date:  2019-02-06       Impact factor: 5.128

9.  A call for evidence-based medical treatment of opioid dependence in the United States and Canada.

Authors:  Bohdan Nosyk; M Douglas Anglin; Suzanne Brissette; Thomas Kerr; David C Marsh; Bruce R Schackman; Evan Wood; Julio S G Montaner
Journal:  Health Aff (Millwood)       Date:  2013-08       Impact factor: 6.301

10.  Factors associated with the prescribing of buprenorphine or methadone for treatment of opiate dependence.

Authors:  Gayle Ridge; Michael Gossop; Nicholas Lintzeris; John Witton; John Strang
Journal:  J Subst Abuse Treat       Date:  2008-11-11
View more
  24 in total

1.  Dismantling War on Drugs Policies in COVID-19's Aftermath.

Authors:  Hannah L F Cooper; David H Cloud; Laura C Fanucchi; Michelle Lofwall; April M Young
Journal:  Am J Public Health       Date:  2022-02       Impact factor: 9.308

2.  Simulating the impact of Addiction Consult Services in the context of drug supply contamination, hospitalizations, and drug-related mortality.

Authors:  Caroline A King; Ryan Cook; Haven Wheelock; P Todd Korthuis; Judith M Leahy; Amelia Goff; Cynthia D Morris; Honora Englander
Journal:  Int J Drug Policy       Date:  2021-11-24

3.  COVID-19-related policy changes for methadone take-home dosing: A multistate survey of opioid treatment program leadership.

Authors:  Ximena A Levander; Jarratt D Pytell; Kenneth B Stoller; P Todd Korthuis; Geetanjali Chander
Journal:  Subst Abus       Date:  2021-10-19       Impact factor: 3.716

4.  Comparing the feasibility of four web-based recruitment strategies to evaluate the treatment preferences of rural and urban adults who misuse non-prescribed opioids.

Authors:  Elizabeth C Saunders; Alan J Budney; Patricia Cavazos-Rehg; Emily Scherer; Lisa A Marsch
Journal:  Prev Med       Date:  2021-09-07       Impact factor: 4.018

5.  Management of opioid use disorder, opioid withdrawal, and opioid overdose prevention in hospitalized adults: A systematic review of existing guidelines.

Authors:  Susan L Calcaterra; Richard Bottner; Marlene Martin; Honora Englander; Zoe M Weinstein; Melissa B Weimer; Eugene Lambert; Matthew V Ronan; Sergio Huerta; Tauheed Zaman; Monish Ullal; Alyssa F Peterkin; Kristine Torres-Lockhart; Megan Buresh; Meghan T O'Brien; Hannah Snyder; Shoshana J Herzig
Journal:  J Hosp Med       Date:  2022-07-26       Impact factor: 2.899

Review 6.  Changing Outdated Methadone Regulations That Harm Pregnant Patients.

Authors:  John J McCarthy; Hendree E Jones; Mishka Terplan; Vania P Rudolf; Melinda Campopiano von Klimo
Journal:  J Addict Med       Date:  2021-04-01       Impact factor: 3.702

7.  Expanding access to methadone treatment in Ohio through federally qualified health centers and a chain pharmacy: A geospatial modeling analysis.

Authors:  Suzan Iloglu; Paul J Joudrey; Emily A Wang; Thomas A Thornhill; Gregg Gonsalves
Journal:  Drug Alcohol Depend       Date:  2021-01-19       Impact factor: 4.492

8.  Research priorities for expanding access to methadone treatment for opioid use disorder in the United States: A National Institute on Drug Abuse Center for Clinical Trials Network Task Force report.

Authors:  Paul J Joudrey; Gavin Bart; Robert K Brooner; Lawrence Brown; Julie Dickson-Gomez; Adam Gordon; Sarah S Kawasaki; Jane M Liebschutz; Edward Nunes; Dennis McCarty; Robert P Schwartz; José Szapocnik; Madhukar Trivedi; Judith I Tsui; Arthur Williams; Li-Tzy Wu; David A Fiellin
Journal:  Subst Abus       Date:  2021       Impact factor: 3.716

9.  Robustness of estimated access to opioid use disorder treatment providers in rural vs. urban areas of the United States.

Authors:  Mathew V Kiang; Michael L Barnett; Sarah E Wakeman; Keith Humphreys; Alexander C Tsai
Journal:  Drug Alcohol Depend       Date:  2021-09-24       Impact factor: 4.492

10.  Opioid treatment program and community pharmacy collaboration for methadone maintenance treatment: results from a feasibility clinical trial.

Authors:  Li-Tzy Wu; William S John; Eric D Morse; Steve Adkins; Jennifer Pippin; Robert K Brooner; Robert P Schwartz
Journal:  Addiction       Date:  2021-08-16       Impact factor: 6.526

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.